Business Context and Reporting Period
This Form 8-K was filed by Leap Therapeutics, Inc. on March 23, 2018. The registrant is a Delaware corporation and an emerging growth company. The filing reports the entry into a material definitive agreement regarding an underwritten public offering of common stock.
Key Financial Metrics and Transaction Details
- Shares Offered: 1,866,667 shares of common stock.
- Public Offering Price: $7.50 per share.
- Underwriting Price: $7.05 per share (representing a 6.0% discount).
- Over-Allotment Option: Underwriters have a 30-day option to purchase up to 280,000 additional shares.
- Expected Net Proceeds: Approximately $12.8 million (excluding over-allotment exercise and after deducting discounts, commissions, and estimated expenses).
- Expected Closing Date: March 27, 2018.
Material Changes and Use of Proceeds
The primary material change is the execution of the Underwriting Agreement with Raymond James & Associates, Inc. and Ladenburg Thalmann & Co. Inc. as book-running managers. The filing text does not provide comparative financial metrics (revenue, profit, cash flow, or debt) for prior periods as this is a current report on a specific transaction rather than a periodic financial statement.
The Company intends to use the net proceeds for general corporate purposes, including:
- Funding new clinical trials for DKN-01 and TRX518.
- Continuation of ongoing studies.
- Capital expenditures, working capital, and general and administrative expenses.
Management Commentary, Risks, and Contingencies
Lock-Up Agreement: Certain officers, directors, and five percent shareholders have agreed not to sell or dispose of their common stock for 60 days following the agreement date without written consent from the underwriters.
Legal and Regulatory: The offering is conducted pursuant to an effective shelf registration statement (No. 333-223419) declared effective on March 16, 2018. The transaction is subject to customary closing conditions and indemnification obligations under the Securities Act of 1933.
Risks: The filing notes that representations and warranties are subject to limitations and confidential disclosures exchanged between parties. The closing is contingent upon the satisfaction of customary conditions.
Investor Verification Checklist
- Verify the final closing of the transaction on or around March 27, 2018.
- Confirm whether the underwriters exercised the 280,000 share over-allotment option.
- Review the final prospectus supplement for updated use of proceeds and risk factors.
- Monitor the progress of clinical trials for DKN-01 and TRX518 as the primary use of capital.
- Check for any subsequent filings regarding the expiration or waiver of the 60-day lock-up period.